{"prompt": "['Protocol', 'ALXN1210-MG-306 Amendment 2', '10.3.', 'Appendix 3: Adverse Events: Definitions and Procedures for', 'Recording, Evaluating, Follow-up, and Reporting', '10.3.1.', 'Adverse Event', 'Adverse Event Definition', 'An AE is any untoward medical occurrence in a patient administered a pharmaceutical product and', 'which does not necessarily have a causal relationship with this treatment. An AE can therefore be any', 'unfavorable or unintended sign (eg, an abnormal laboratory finding), symptom, or disease temporally', 'associated with the use of a medicinal product, whether or not considered related to the medicinal', 'product.', 'Events Meeting the Adverse Event Definition', 'Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other safety', 'assessments (eg, ECG, radiological scans, vital signs measurements), including those that worsen from', 'baseline, considered clinically significant in the medical and scientific judgment of the Investigator (ie,', 'not related to progression of underlying disease).', 'Exacerbation of a chronic or intermittent pre-existing condition including either an increase in', 'frequency and/or intensity of the condition.', 'New conditions detected or diagnosed after study intervention administration even though it may have', 'been present before the start of the study.', 'Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.', '\"Lack of efficacy\" or \"failure of expected pharmacological action\" per se will not be reported as an AE', 'or SAE. Such instances will be captured in the efficacy assessments. However, the signs, symptoms,', 'and/or clinical sequelae resulting from lack of efficacy will be reported as AE or SAE if they fulfil the', 'definition of an AE or SAE.', 'Events NOT Meeting the Adverse Event Definition', 'Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to the', 'procedure is the AE. Situations in which an untoward medical occurrence did not occur (eg,', 'hospitalization for elective surgery if planned before the signing the ICF, admissions for social reasons', 'or for convenience).', 'Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present or detected at the', 'start of the study that do not worsen.', 'Lack of drug effect is not an AE in clinical studies, because the purpose of the clinical study is to', 'establish drug effect.', 'A medication error (including intentional misuse, abuse, and overdose of the product) or use other than', 'what is defined in the protocol is not considered an AE unless there is an untoward medical occurrence', 'as a result of a medication error.', 'Cases of pregnancy that occur during maternal or paternal exposure to study drug are to be reported', 'within 24 hours of Investigator/site awareness. Data on fetal outcome and breastfeeding will be', 'collected for regulatory reporting and safety evaluation.', 'Page 73 of 109', 'Alexion Confidential']['Protocol', 'ALXN1210-MG-306 Amendment 2', '10.3.2.', 'Serious Adverse Event', 'If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions', 'are met (eg, hospitalization for signs/symptoms of the disease under study, death due to', 'progression of disease).', 'A serious adverse event is defined as any untoward medical occurrence that, at any dose:', 'Results in death', 'Is life-threatening', 'The term \"life-threatening\\' in the definition of \\'serious\\' refers to an event in which the participant was at', 'risk of death at the time of the event. It does not refer to an event, which hypothetically might have caused', 'death, if it were more severe.', 'Requires inpatient hospitalization or prolongation of existing hospitalization', 'In general, hospitalization signifies that the patient has been detained (usually involving at least an', 'overnight stay) at the hospital or emergency ward for observation and/or treatment that would not have', \"been appropriate in the physician's office or outpatient setting. Complications that occur during\", 'hospitalization are AEs. If a complication prolongs hospitalization or fulfills any other serious criteria, the', 'event is serious. When in doubt as to whether \"hospitalization\" occurred or was necessary, the AE should', 'be considered serious.', 'Hospitalization for elective treatment of a pre-existing condition that did not worsen from baseline is not', 'considered an AE.', 'Results in persistent disability/incapacity', \"The term disability means a substantial disruption of a person's ability to conduct normal life functions.\", 'This definition is not intended to include experiences of relatively minor medical significance such as', 'uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankle)', 'which may interfere with or prevent everyday life functions but do not constitute a substantial disruption.', '1. Is a congenital anomaly/birth defect', '2. Other situations:', 'Medical or scientific judgment should be exercised in deciding whether SAE reporting is appropriate in', 'other situations such as important medical events that may not be immediately life-threatening or result in', 'death or hospitalization but may jeopardize the participant or may require medical or surgical intervention', 'to prevent one of the other outcomes listed in the above definition. These events should usually be', 'considered serious.', '10.3.3.', 'Suspected Unexpected Serious Adverse Reactions', 'Suspected Unexpected Serious Adverse Reactions Definition', 'Suspected unexpected serious adverse reactions (SUSARs) are serious events that are not listed in the IB', 'and that the Investigator identifies as related to study drug or procedure. The US 21CFR312.32 and EU', 'Clinical Trial Directive 2001/20/EC and the associated detailed guidance documents or national', 'regulatory requirements in participating countries require the reporting of SUSARs. Alexion has', 'procedures that will be followed for the recording and expedited reporting of SUSARs that are consistent', 'with global regulations and the associated detailed guidance documents. Suspected unexpected serious', 'adverse reactions will be reported to the national competent authority and IRBs/IECs where applicable.', 'Page 74 of 109', 'Alexion Confidential']\n\n###\n\n", "completion": "END"}